Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Deffered Revenue: 2020-2025

Historic Non-Current Deffered Revenue for IDEAYA Biosciences (IDYA) over the last 2 years, with Sep 2025 value amounting to $1.7 million.

  • IDEAYA Biosciences' Non-Current Deffered Revenue was N/A to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2022, which is 83.38% down from last year.
  • Latest data reveals that IDEAYA Biosciences reported Non-Current Deffered Revenue of $1.7 million as of Q3 2025, which was down 67.68% from $5.2 million recorded in Q4 2022.
  • IDEAYA Biosciences' 5-year Non-Current Deffered Revenue high stood at $52.1 million for Q1 2021, and its period low was $1.7 million during Q3 2025.
  • Moreover, its 1-year median value for Non-Current Deffered Revenue was $1.7 million (2025), whereas its average is $1.7 million.
  • Data for IDEAYA Biosciences' Non-Current Deffered Revenue shows a maximum YoY slumped of 83.38% (in 2022) over the last 5 years.
  • IDEAYA Biosciences' Non-Current Deffered Revenue (Quarterly) stood at $31.2 million in 2021, then crashed by 83.38% to $5.2 million in 2022, then reached $1.7 million in 2025.
  • Its Non-Current Deffered Revenue stands at $1.7 million for Q3 2025, versus $5.2 million for Q4 2022 and $7.3 million for Q3 2022.